The Future Of Biopharma Manufacturing Has Never Been More Critical

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

What good is any biopharmaceutical R&D pipeline if you can’t manufacture at the quantity and quality necessary to deliver to patients in need? We’ve heard plenty of hype around all the remarkable efforts to develop COVID-19 diagnostics, therapeutics, and vaccines. And while we are all pulling for there to be many more coronavirus-related R&D successes than failures, it will be our ability to manufacture at scale that will save the day. Sure, 2020 is the year that pretty much changed everything. But the one thing it didn’t change is how critical biopharmaceutical manufacturing is to the human race. The reality is cancers and other fatal ailments never went on lockdown — and for the most part, neither did biopharmaceutical manufacturing. Here’s what six biopharmaceutical manufacturing executives have to say on emerging manufacturing innovations, key trends to pay attention to in 2021 (and beyond), and so much more.